Author's reply to comments to: Clinical experience of switching anti-VEGF therapy from ranimizumab to aflibercept in age-related choroidal neovascularization

Eur J Ophthalmol. 2017 May 11;27(3):e109. doi: 10.5301/ejo.5000931.
No abstract available

Publication types

  • Comment

MeSH terms

  • Bevacizumab
  • Choroidal Neovascularization*
  • Humans
  • Receptors, Vascular Endothelial Growth Factor
  • Recombinant Fusion Proteins
  • Vascular Endothelial Growth Factor A*

Substances

  • Recombinant Fusion Proteins
  • Vascular Endothelial Growth Factor A
  • aflibercept
  • Bevacizumab
  • Receptors, Vascular Endothelial Growth Factor